Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Triaziquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 2/20 | 0.38 |
| ▸ | TDP2 | O95551 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 2/20 | 0.38 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GALK1 | P51570 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL11120458 | 0.96 | DNMT1 (0.46) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL9468685 | 0.96 | DNMT1 (0.46) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL7088197 | 0.93 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL8972318 | 0.93 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL6336233 | 0.93 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL9876358 | 0.93 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL3101456 | 0.93 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL5054475 | 0.93 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL6000230 | 0.93 | DNMT1 (0.47) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL19995413 | 0.91 | DNMT1 (0.46) | DNMT1MAPTHTTTP53STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9285289-A | — | — | None | — | — | JP | disclosed |
| US-20230312734-A1 | STABLE PHARMACEUTICAL FORMULATION, VIAL, CARTRIDGE, PRE-FILLED SYRINGE AND AUTO-INJECTOR COMPRISING THE SAME | CELLTRION INC. (KR) | 2023-10-05 | — | — | US | disclosed |
| EP-4205765-A2 | STABLE PHARMACEUTICAL PREPARATION | Celltrion, Inc. (KR) | 2023-07-05 | — | — | EP | disclosed |
| CN-115427425-A | Adalimumab non-protein A purification method | 普莱斯蒂生物制药私人有限公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2022045857-A2 | STABLE PHARMACEUTICAL PREPARATION | (주)셀트리온 | 2022-03-03 | — | — | WO | disclosed |
| US-20170327802-A1 | Anti-Inflammatory Peptides and Composition Comprising the Same | GEMVAX & KAEL CO., LTD. (KP) | 2017-11-16 | — | — | US | disclosed |
| US-9631184-B2 | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate | GEMVAX & KAEL CO., LTD. (KR) | 2017-04-25 | — | — | US | disclosed |
| US-20170073667-A1 | METHOD FOR MANIPULATING MAGNETIC PARTICLES AND DEVICE FOR MANIPULATING MAGNETIC PARTICLES | SHIMADZU CORPORATION (JP) | 2017-03-16 | — | — | US | disclosed |
| CN-103649327-B | Specific A1AT monoclonal antibody for detecting endometriosis | 台北医学大学 | 2016-10-26 | — | — | CN | disclosed |
| US-20160002613-A1 | Cell Penetrating Peptide, Conjugate Comprising Same, and Composition Comprising Conjugate | GEMVAX & KAEL CO., LTD. (KR) | 2016-01-07 | — | — | US | disclosed |
| US-8759617-B2 | Method for extraction and purification of recombinant proteins from transgenic plants | NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES (JP) | 2014-06-24 | — | — | US | disclosed |
| US-20120142033-A1 | METHOD FOR EXTRACTION AND PURIFICATION OF RECOMBINANT PROTEINS FROM TRANSGENIC PLANTS | PrevenTec, Inc. (JP) | 2012-06-07 | — | — | US | disclosed |
| CN-100593721-C | Immunoassay and kit for early and simultaneous detection of biochemical markers in a sample of a patient | DIAGENICS INTERNAT CORP | 2010-03-10 | — | — | CN | disclosed |
| CN-1618017-A | Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample | DIAGENICS INTERNAT CORP (US) | 2005-05-18 | — | — | CN | disclosed |
| US-6342367-B1 | TREATMENT OF FISH SCALES WITH ENZYME FOR DISSOLVING, ADDING WATER TO FORM SOLUTIONS AND REMOVAL OF POLYPEPTIDES BY-PRODUCTS | JAPAN AS REPRESENTED BY SECRETARY OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2002-01-29 | — | — | US | disclosed |
| JP-H09285289-A | SYNTHESIS OF POLYDEOXYRIBONUCLEOTIDE | TAIKO YAKUHIN KK | 1997-11-04 | — | — | JP | disclosed |
| US-5145844-A | Enzyme inhibitors, antiinflammatory agents, analgesics | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-09-08 | — | — | US | disclosed |
| US-5030733-A | Analgesics, antiinflammatory agents, phospholipase inhibitor | HOECHST-ROUSSEL PHARMACETICALS INCORPORATED (US) | 1991-07-09 | — | — | US | disclosed |
| EP-0300397-A2 | Hydroxy-, Alkoxy- and Benzyloxy substituted phospholipids, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002613-A1 | Cell Penetrating Peptide, Conjugate Comprising Same, and Composition Comprising Conjugate | NGLY1, VIP, SLC7A1 | DNMT1 1941/4885MAPT 2370/4885HTT 2015/4885 |
| US-20170327802-A1 | Anti-Inflammatory Peptides and Composition Comprising the Same | IL1B, IL1A, TNF | DNMT1 1141/4885MAPT 3442/4885HTT 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.